Evidence-Based Reviews

Borderline, bipolar, or both? Frame your diagnosis on the patient history

Author and Disclosure Information

 

References

Mood reactivity can occur within episodes of bipolar disorder, although episodes may occur spontaneously and without an obvious precipitant or stressor. Impulsivity may represent more of an essential feature of BPD than affective instability or mood reactivity and may be of particular diagnostic relevance.

Treatment implications

When you are unable to make a clear diagnosis, describe your clinical reasoning and differential diagnosis in the assessment or formulation. With close follow-up, the longitudinal history and course of illness may eventually lead you to an accurate diagnosis.

There are good reasons to acknowledge both conditions when bipolar disorder and BPD are present. Proper recognition of bipolar disorder is a prerequisite to taking full advantage of proven pharmacologic treatments. The evidence base for pharmacologic management of BPD remains limited,31 but recognizing this disorder may help the patient understand his or her psychiatric history and encourage the use of effective psychosocial treatments.

Psychosocial treatments for bipolar disorder may target demoralization and circadian rhythms with sleep hygiene or social rhythms therapy. Acknowledging BPD:

  • helps both clinician and patient to better understand the condition
  • facilitates setting realistic treatment goals because BPD tends to respond to medication less robustly than bipolar disorder.

Recognizing BPD also allows for referral to targeted psychosocial treatments, including dialectical behavior therapy, mentalization-based treatment, or Systems Training for Emotional Predictability and Problem Solving (STEPPS).32-34

Related resources

Drug brand name

  • Divalproex • Depakote, Depakene, others

Disclosures

Dr. Fiedorowicz reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Dr. Black receives research/grant support from AstraZeneca and Forest Laboratories and is a consultant to Jazz Pharmaceuticals.

Acknowledgment

The authors would like to thank Nancee Blum, MSW, and Nancy Hale, RN, for their assistance and expertise in the preparation of this article.

Pages

Recommended Reading

Bipolar moving target: Draw a bead on rapid cycling with type-specific therapies
MDedge Psychiatry
Commentary: When medical illness complicates schizophrenia and bipolar disorder
MDedge Psychiatry
What would Confucius say about mood stabilizers?
MDedge Psychiatry
Bipolar MANIAS: Life events help confirm the diagnosis
MDedge Psychiatry
Controversies in bipolar disorder: Trust evidence or experience?
MDedge Psychiatry
Help your bipolar disorder patients remain employed
MDedge Psychiatry
Asenapine for schizophrenia and bipolar I disorder
MDedge Psychiatry
Acute bipolar mania: Aggressive initial dosing provides faster symptom relief
MDedge Psychiatry
Unipolar depression or "soft" bipolar disorder? Tips to avoid misdiagnosis
MDedge Psychiatry
Tips to differentiate bipolar II disorder and borderline personality disorder
MDedge Psychiatry